Stay updated on FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial
Sign up to get notified when there's something new on the FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial page.

Latest updates to the FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange Detected- The page revision was updated from v3.5.2 to v3.5.3, indicating a new site release. This update is metadata-only and does not modify study content or displayed information.SummaryDifference0.1%

- Check21 days agoChange DetectedNo website changes were detected from the provided additions/deletions inputs.SummaryDifference0.0%

- Check28 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.0%

- Check43 days agoChange DetectedB-cell chronic lymphocytic leukemia was added to the list of conditions in the study details. This expands the study description to include CLL cohorts.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.0%

- Check64 days agoChange DetectedRevision metadata updated: v3.4.3 added and v3.4.2 removed; no substantive content on the page was changed.SummaryDifference0.0%

Stay in the know with updates to FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FT596 in Monotherapy and Combo with Anti-CD20 mAbs Clinical Trial page.